[Influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B].
OBJECTIVE
To explore influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B.


METHODS
74 cases of CHB were randomly divided into two groups, 36 cases in treatment group, treated with 600 mg Kurarinol glucose injection, IV, once a day. After one month, Kurarinol capsule was used orally, three times a day for 2 months, 200 mg Silybin Meglumine Tablets orally, three times a day for 3 months. 38 cases in control group, only Silybin Meglumine Tablets was used, method and dosage were the same as treatment group. Compare HBV specific CTL, non-specific CTL, sub-group of T cells, changes of Th1 and Th2, negative conversion rate of HBV DNA and HBeAg of the two groups.


RESULTS
In treatment group, 3 months after treatment with Kurarinol, HBV specific CTL is higher than that before treatment (P < 0.01), it is also higher than that of control after treatment, P < 0.05) . Non-specific CTL is higher than that before treatment (P < 0.05), it is also higher than that of control after treatment (P < 0.01). CD4 is higher than that before treatment (P <0.05), it is also higher than that of control after treatment (P < 0.01), Thl is higher than that before treatment (P < 0.05), it is also higher than that of control after treatment (P < 0.01) . Negative conversion of HBV DNA and HBeAg is higher than that of control (P < 0.01).


CONCLUSIONS
Kurarinol can improve specific and non-specific cell immunity in patients with CHB. It is one of the mechanisms that Kurarinol can clear or inhibit HBV of patients with CHB.
Gu
Xi-Bing
XB
Jiangsu Wuxi Hospital for Infectious Diseases, 214005, China. gxb188681@sina.com
Yang
Xiao-Juan
XJ
Wang
Dong
D
Zhu
Yin-Fang
YF
Ding
Hong
H
Zhang
Bo
B
Xu
Yue-Qin
YQ
Wu
Hang-Yuan
HY
D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D000077385:Silybin; D012838:Silymarin / Q000008:administration & dosage; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D055815:Young Adult
D005419:Flavonoids; D012838:Silymarin; C526229:kurarinol; D000077385:Silybin